<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20190703044082N13</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2025-10-10</date_registration>
      <primary_sponsor>Hamedan University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of the effect of virtual reality-based games and cartoon watching on anxiety, fear, and pain in children with acute lymphoblastic leukemia during chemotherapy</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the effect of virtual reality-based games and cartoon watching on anxiety, fear, and pain in children with acute lymphoblastic leukemia during chemotherapy</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2025-09-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>93</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/85454</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive, Randomization description: For random allocation into three groups (playing with virtual reality, watching cartoons with virtual reality, and control), a block randomization method with blocks of 6 will be used. This method involves creating 20 blocks of 6 units each (60 combinations), with each block including two participants for each group. The three letters A (playing with virtual reality), B (watching cartoons with virtual reality), and C (control) are written on pieces of paper and placed in an envelope. The random order of drawing the letters determines the groups, for example, A for playing with virtual reality, B for watching cartoons with virtual reality, and C for control. Then, 20 blocks of six-letter combinations such as AABBCC and ABCABC are written on paper and placed in an envelope. The blocks are selected randomly with replacement. Children are assigned to groups based on the order of the selected blocks.</study_design>
      <phase>N/A</phase>
      <hc_freetext>cancer.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: In group A (virtual reality game): First, a 3D game suitable for the child's gender and interests is selected. Then, the game is started using virtual reality glasses 10 minutes before the start of chemotherapy and continues throughout the chemotherapy session (approximately one hour). Pain intensity, fear, and anxiety will be assessed 10 minutes before chemotherapy, during chemotherapy, and immediately after chemotherapy. Intervention 2: Intervention group: Intervention group: In group B (watching cartoons with virtual reality): First, a 3D cartoon suitable for the child's gender and interests is selected. Then, watching the cartoon using virtual reality glasses begins 10 minutes before the start of chemotherapy and continues throughout the chemotherapy session (approximately one hour). The intensity of pain, fear, and anxiety will be assessed 10 minutes before chemotherapy, during, and immediately after chemotherapy. Intervention 3: Control group: In group C (control): No virtual reality-based intervention is received. However, children can use routine activities such as playing or watching movies with their parents' mobile phones, but these activities will be without virtual reality technology. The intensity of pain, fear, and anxiety will be assessed 10 minutes before chemotherapy, during, and immediately after chemotherapy.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no further information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Fateme Mohammadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Hamadan University of Medical sciences, Khajeh Rashid Blvd</address>
        <city>Hamadan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6517838698</zip>
        <telephone>+98 81 3334 5634</telephone>
        <email>mohammadifateme47@yahoo.com</email>
        <affiliation>Hamedan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Fateme Mohammadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Hamadan University of Medical sciences, Khajeh Rashid Blvd</address>
        <city>Hamadan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6517838698</zip>
        <telephone>+98 81 3334 5634</telephone>
        <email>mohammadifateme47@yahoo.com</email>
        <affiliation>Hamedan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Acute lymphoblastic leukemia
Age 6 to 12 years
First course of chemotherapy
No speech, vision, or hearing disorders, or mental retardation
No neurological deficits affecting pain perception based on medical records
In stage one (Induction Phase) or stage two (Consolidation Phase) of cancer
Under treatment with L-asparaginase
Willingness to participate in the study
Non-dominant arm line is fixed.</inclusion_criteria>
      <agemin>6 years</agemin>
      <agemax>12 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Reluctance to continue the study process
Development of poisoning from chemotherapy drugs
Occurrence of emergency situations such as cardiopulmonary resuscitation or seizure, etc
Not playing games or watching with virtual reality glasses for more than 10 minutes</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: In group A (virtual reality game): First, a 3D game suitable for the child's gender and interests is selected. Then, the game is started using virtual reality glasses 10 minutes before the start of chemotherapy and continues throughout the chemotherapy session (approximately one hour). Pain intensity, fear, and anxiety will be assessed 10 minutes before chemotherapy, during chemotherapy, and immediately after chemotherapy.</i_keyword>
      <i_keyword>Intervention group: Intervention group: In group B (watching cartoons with virtual reality): First, a 3D cartoon suitable for the child's gender and interests is selected. Then, watching the cartoon using virtual reality glasses begins 10 minutes before the start of chemotherapy and continues throughout the chemotherapy session (approximately one hour). The intensity of pain, fear, and anxiety will be assessed 10 minutes before chemotherapy, during, and immediately after chemotherapy.</i_keyword>
      <i_keyword>Control group: In group C (control): No virtual reality-based intervention is received. However, children can use routine activities such as playing or watching movies with their parents' mobile phones, but these activities will be without virtual reality technology. The intensity of pain, fear, and anxiety will be assessed 10 minutes before chemotherapy, during, and immediately after chemotherapy.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain intensity. Timepoint: Before starting chemotherapy, during chemotherapy, and after completing chemotherapy. Method of measurement: Oucher Pain Scale.</prim_outcome>
      <prim_outcome>Fear. Timepoint: Before starting chemotherapy, during chemotherapy, and after completing chemotherapy. Method of measurement: Children's Fear Scale.</prim_outcome>
      <prim_outcome>Anxiety. Timepoint: Before starting chemotherapy, during chemotherapy, and after completing chemotherapy. Method of measurement: Visual-Facial-Anxiety-Scale.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Hamadan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2025-09-22</approval_date>
        <contact_name>Research ethics committee of Hamadan University of Medical Sciences</contact_name>
        <contact_address>Hamadan University of Medical sciences, Khajeh Rashid Blvd Hamadan Hamadan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
